Katerina deals with Corporate and Commercial & Employment law issues. She joined K&P in January 2022.
Our firm acts as Greek legal counsel to J.P. Morgan in connection with its strategic investment in Viva Wallet
K&P advised HELPE Group in relation to its corporate transformation plan
K&P 2021 Highlights
K&P advises Eurobank on the sale of 80% of its merchant acquiring business to Worldline
Employment law reforms introduced by law 4808/2021
K&P is the exclusive contributor of the Greek chapter in Chambers & Partners Blockchain 2021 Global practice guide
K&P proudly sponsored the 13th National Conference of Corporate In house Counsel by NOMIKI BIBLIOTHIKI
K&P advised SIDMA Steel S.A.
Karatzas & Partners advised a Spanish multinational group of companies active in the fashion and beauty sectors
Law 4727/2020 – Digital Governance, Public and Private Electronic Documents and E-Signatures
K&P - Update on the regime regarding the facilitation of General Meetings during the Covid19 crisis
K&P sponsors the 12th National Conference of Corporate Inhouse Counsel
K&P at "The new provisions for transactions with related parties" - Webinar
Karatzas & Partners advised Eurobank Ergasias Services & Holdings S.A.
K&P at "The New Greek Insolvency Code" webinar by Capital Link
Covid-19: Greek Corporates - Facilitation of Decision Making for Boards of Directors
Karatzas & Partners advised SIDMA SA
Banking & Finance Alert: Law 4701_2020 on Microcredit Institutions
Service by Electronic Means and Operation of Civil and Administrative Courts from 01.06.2020
2nd Update on the most important emergency measures for businesses issued by the Greek government in order to tackle the adverse effects of the spread of Covid-19 outbreak
How does the COVID-19 pandemic affect your contractual obligations?
Covid-19: Update on the most important emergency measures for businesses issued by the Greek government
Personal Data Processing in the context of Covid-19
Adopted Measures to tackle the adverse effects of the spread of Covid-19 outbreak
Karatzas & Partners advises MS Pharma